



Cite this: *Integr. Biol.*, 2016, 8, 465

Received 25th October 2015,  
Accepted 14th February 2016

DOI: 10.1039/c5ib00267b

[www.rsc.org/ibiology](http://www.rsc.org/ibiology)

## Genetically modified bacteriophages

Antonia P. Sagona,<sup>a</sup> Aurelijā M. Grigonyte,<sup>ab</sup> Paul R. MacDonald<sup>ac</sup> and Alfonso Jaramillo<sup>\*ad</sup>

Phages or bacteriophages, viruses that infect and replicate inside bacteria, are the most abundant microorganisms on earth. The realization that antibiotic resistance poses a substantial risk to the world's health and global economy is revitalizing phage therapy as a potential solution. The increasing ease by which phage genomes can be modified, owing to the influx of new technologies, has led to an expansion of their natural capabilities, and a reduced dependence on phage isolation from environmental sources. This review will discuss the way synthetic biology has accelerated the construction of genetically modified phages and will describe the wide range of their applications. It will further provide insight into the societal and economic benefits that derive from the use of recombinant phages in various sectors, from health to biodetection, biocontrol and the food industry.

### Insight, innovation, integration

In this review, we address the technological advances of synthetic biology that enable the genetic engineering of bacteriophages. Further, we discuss the wide spectrum of applications of genetically engineered bacteriophages.

## 1. Introduction

### 1.1 Why use recombinant phages?

Current advances in synthetic biology have facilitated the rational design, modification and construction of recombinant phages – that contain genetically engineered DNA and/or have been through genetic recombination – enabling the extension of their innate phenotypes. The host specificity of phages is evolutionarily refined, with most phages targeting one species. This host recognition specificity is conferred by receptor binding domains (RBDs) that are found in either the tail-spike or tail fiber protein assemblies of the virions. Many researchers have altered the specificity of phages towards non-native hosts.<sup>1–6</sup> In one such example, the host range of fd filamentous phage is altered by fusing a RBD from another filamentous phage (IK<sub>E</sub>), onto the infection-mediating protein of fd. Moving on to lytic phages, a genetically engineered T4 phage repository, was curated by randomizing the T4 RBD using polymerases with less fidelity to PCR amplify non-conserved regions. The repository was found

to propagate in *Yersinia ruckeri* and *Pseudomonas aeruginosa*, indicating that the host range of T4 had been re-directed from its native *Escherichia coli* host.<sup>2</sup> Similarly, T3 (which naturally infects *E. coli*) and T7 phage (which infects *E. coli* and some species of *Yersinia*) was assembled in *Saccharomyces cerevisiae* with exogenous phage protein domains in order to alter its host range. As a proof of concept, it was demonstrated that modified T3 and T7 phage scaffolds could target pathogenic *Yersinia* and *Klebsiella* bacteria respectively. In addition, *Klebsiella* phage scaffolds were retargeted against *Escherichia coli* by swapping their phage tail components.<sup>3</sup>

Recombinant phages also function as vehicles for antimicrobials that are either incorporated into the phage<sup>7</sup> or attached to its surface.<sup>8</sup> For instance, they have been used to deliver light-activated antimicrobial agents (photosensitizers), which are seen as promising alternatives to antibiotics for treatment of common skin infections.<sup>9</sup> Phages can also be engineered to suppress host SOS DNA repair system, enhancing the effectiveness of broad-spectrum antibiotics *in vitro*.<sup>10</sup> Understandably, a natural concern about using engineered organisms is that the balance between natural phages in the environment may be affected. However, a recent study illustrated that phages endowed with gain of function mutations were out-competed by natural phages specific to the same host, suggesting that engineered phage genomes might not persist in the wild.<sup>11</sup> Additionally, one strategy to

<sup>a</sup> Warwick Integrative Synthetic Biology Centre and School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK.

E-mail: Alfonso.Jaramillo@synth-bio.org

<sup>b</sup> Synthetic Biology Centre for Doctoral Training, University of Warwick, Coventry, CV4 7AL, UK

<sup>c</sup> MOAC DTC, Senate House, University of Warwick, Coventry, CV4 7AL, UK

<sup>d</sup> iSSB, Genopole, CNRS, UEVE, Université Paris-Saclay, Évry, France



commercialize phages is to re-engineer them to be non-replicative or non-lytic.<sup>12,13</sup>

## 1.2 Synthetic biology technologies for phage engineering

**Genome engineering.** A wide range of genome engineering methods have been applied to modify phage genomes and provide the desired characteristics for different applications. For simplicity, we have divided the methods in the text into *in vitro* and *in vivo*.

*a. In vitro methods.* Restriction endonuclease-based methods have been used to construct recombinant genomes *in vitro*. For instance, the genome of T7 was redesigned to remove overlapping genetic elements among other modifications. The new version of the genome (T7.1) is divided into 73 'parts'



**Antonia P. Sagona**

of Warwick (UK) and her work focuses in establishing an *in vitro* novel system for phage therapy, consisting of recombinant phages designed to target a specific pathogen in a mammalian cell environment.

Dr Antonia P. Sagona received her PhD (2012) in cancer cell biology in the laboratory of Professor Harald Stenmark, in the Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo (Norway). She then received an EMBO Postdoctoral long-term fellowship (2013), which was hosted in the Division of Biomedical Cell Biology, Warwick Medical School (UK). She is currently a Research Fellow in the School of Life Sciences, University



**Paul R. MacDonald**

Paul MacDonald is a PhD candidate in MOAC (Molecular Organisation and Assembly in Cells) Doctoral Training Centre, University of Warwick, UK interested in developing proof of concepts for phage therapeutics. Trained in mathematics at the University of Birmingham, UK, his research interests include phage genome engineering, receptor binding proteins and computational modeling.

belonging to six sections. The first two sections of T7.1 were synthesized and shown to be viable.<sup>14</sup>

An additional, *in vitro* method is reported for the genetic modification of lytic phages, called genome recombineering with electroporated DNA (BRED), where they used the P1vir phage as a proof of concept. BRED is based on the use of recombinases (obtained from bacterial heterologous overexpression) to assemble phage genomes from purified phage genome and given synthetic DNA fragments.<sup>15</sup> BRED has been recently used to genetically modify a P1vir phage. Specifically, a copy of the mobile element IS1 was removed from the genome of P1vir phage, with the use of BRED.<sup>16</sup>

*b. In vivo methods.* *In vivo* methods have been used for bacteriophage engineering involving marker-based or marker-less selections of genetically modified bacteriophages. The most



**Aurelija M. Grigonyte**

bacteriophage and mammalian cells; using engineered bacteriophages for treatment against variety of pathogens.

Aurelija Marija Grigonyte is a PhD candidate in synthetic biology at SynBio Centre for Doctoral Training, University of Warwick, UK. Originally trained in biochemistry she is now working on engineering synthetic bacteriophages. Her main research interests include: understanding the key variants responsible for bacteriophage to its target binding; broadening bacteriophage host range; interactions between modified



**Alfonso Jaramillo**

Professor Alfonso Jaramillo holds a PhD in Particle Physics (1999) and a Habilitation in Biology (2007). After postdoctoral appointments with Prof. Wodak (ULB, Brussels) and Prof. Karplus (ULP, France and Harvard, USA), he started his academic career in 2003 as Assistant Professor at the Ecole Polytechnique (France), becoming tenured in 2005. There, he further developed computational synthetic biology.

In 2009, after moving to Genopole (France) as CNRS-senior researcher, he started his experimental synthetic biology lab, utilizing directed evolution, microscopy, microfluidics and 3D printing. In 2013, he opened a second lab at the University of Warwick (UK), where he holds the Chair of Synthetic Biology.



commonly used *in vivo* method is homologous recombination (HR), where the sequence to be inserted is cloned into a vector with flanking regions matching upstream and downstream of phage genome sequence. Phage that has undergone HR can then be selected from the phage population, with the methods described below.

Marker-based selection methods exploit genes promoting phage propagation. They could be genes encoded in the phage genome or host factors required for phage propagation. For the former, the gene has to be previously deleted from the genome, where the phage may require a strain expressing such gene to propagate. A first step would consist of the homologous recombination of the insert and the gene marker. Later, a marker-deficient strain could be used for selection. Alternatively, a host factor can be used. For instance, in order to identify a marker for T7 selection, *E. coli* BW25113 is screened for genes that promote T7 phage growth, and these can be used as selection markers when editing T7 phage genome. Two potential genes are identified: *cmk* and *trxA*. Deletion of the *trxA* gene appears to confer phage infection inhibition, whereas deletion of the *cmk* gene in the bacterial host shows a lower efficiency of plating of T7 bacteriophage in comparison to the control bacteria. The reduced efficiency of plating, but not a complete absence of plaques, indicates that despite the gene deletion, some degree of T7 infection is obtained. These false positives can be removed by serial dilutions. In this study the *E. coli* gene *cmk*, which encodes for CMP/dCMP kinase, was inserted instead of T7 gp5 by HR between wild-type T7 and a plasmid containing the *cmk* gene. The plated recombined phage was shown to be negative for growth on cells that were deficient in *cmk*, and which did not contain a plasmid expressing gp5. This expected phenotype was confirmed to be true at the genotypic level by sequencing.<sup>17</sup>

False positives may occur in the marker-less selection method, CRISPR/Cas.<sup>18</sup> In a recent report, CRISPR/Cas system, and specifically type I-E CRISPR/Cas system, was used to select for engineered T7 bacteriophage (see Fig. 1). The T7 phage genome was edited by homologous recombination and the recombinant phages were selected by targeting wild-type phages with the CRISPR/Cas system.<sup>19</sup>

In another report, in addition to using CRISPR/Cas for the selection of engineered phage, CRISPR/Cas II-A system was used to *in vivo* modify phage 2972. Phage genome editing included gene exchange, point mutation and small or large deletions. For the gene exchange, *orf33* in the phage 2972 was replaced with methyltransferase gene of the type II restriction/modification (R/M) system LlaDCHI from *L. lactis*. Since the results showed a successful gene swap and a fully functioning methyltransferase it was concluded that the CRISPR/Cas engineering system can be used for gene insertions into the phage's genome.<sup>20</sup> CRISPR/Cas technology could be adapted to other phage genomes.

In another example, bacteriophage engineering is accomplished using an *in vivo* yeast platform as an alternative host for bacteriophage assembly. This platform is used to engineer phage with novel host ranges by swapping viral tail fibre scaffolds.




Fig. 1 Summary of CRISPR/Cas system used for recombinant phage selection *via* non-edited genome targeting. (a) The DNA of wild type (WT) bacteriophage (in light blue) undergoes homologous recombination following infection of the recombinant strain. The recombination strain contains a plasmid with a sequence (in violet) with flanking homology regions that replaces the WT phage genome sequence (in blue). This infection results in mixed population of phage progeny, producing recombinant phage (in violet) in addition to the WT phage (in blue). (b) The selection strain contains a CRISPR-Cas system, which targets and cleaves the WT sequence. Phages can still propagate in this strain, either because of inefficiencies associated with the CRISPR machinery, or because they contain one or more SNPs in the region targeted by the Cas-gRNA complex (deemed escape mutants). (c) The CRISPR-Cas system does not complex with the recombinant phage, resulting in relatively more progeny.

Phage genomes are placed in *Saccharomyces cerevisiae*, allow gene modifications and result in generation of engineered phage. Each fragment of the phage genome is first amplified by PCR while retaining a homologous overhang. First and last fragments of the phage genome have a homology region with the yeast artificial chromosome (YAC). All amplified phage genome fragments as well as YAC are then transformed into yeast where gap repair facilitated joining of all the fragments and the YAC according to homology regions. After the purification of the vector the phage can then be initiated to form functional phages when transformed into bacteria. This yeast phage-engineering platform has a great potential because any genomic loci can be modified even by adding genes toxic to *E. coli*.<sup>3</sup> One possible inconvenience is that the phage may have repeats at their ends (as it is the case for T7) and recombination may produce excision of the phage from the vector. This may be overcome by including a selective marker for yeast inside the phage genome.

**Directed evolution methodologies.** Directed evolution may be used to alter and optimize bacteriophage genomes providing a phenotypic or genotypic advantage in a given environment. It is possible to evolve bacteriophages *via* serial passaging, or



continuous culture in a bioreactor.<sup>21</sup> This platform was used to evolve lambda phage, which normally infects its host *via* LamB protein receptor, to infect *via* a novel OmpF receptor.<sup>4</sup> In another remarkable study, a phage was optimized by serial passages in a living mouse providing a 13 000 fold greater capacity of the phage to evade immune system and remain in the circulatory system. This was a result of a single mutation which led to amino acid substitution in the major lambda phage capsid protein E.<sup>22</sup>

PACE (phage-assisted continuous evolution) combines continuous culture with increased mutagenesis to accelerate the evolution of M13 phagemids (non-replicative phages that require a strain carrying a helper system). PACE is used to evolve regulatory molecules rather than structural proteins in the virion. This is done by removing an essential gene (gpIII) from the phage and placing it, in an inactivated form, in the host strain. The gene responsible for the initiation of the evolution is introduced into the phage. The product of this gene must activate gpIII to produce infectious progeny. It is possible to use a similar methodology to evolve proteins from the phage such as those conferring host specificity or involved in replication.<sup>23</sup> This method has been further expanded to evolve biomolecules with altered or highly specific new activities, using negative selection and modulation of selection stringency.<sup>24</sup>

**Phage display.** Phage display is based on generating a library of synthetic or natural peptides and then fusing them onto a coat protein of a bacteriophage. Modified phages that bind strongly to the ligand displayed are enriched *via* sequential recovery from the surface and upon that they re-infect bacteria to propagate and increase in number. Filamentous phages M13<sup>25–33</sup> and fd<sup>34–36</sup> are the most commonly used phages for phage display although T4,<sup>37,38</sup> T7<sup>39–43</sup> and lambda<sup>44–47</sup> phages have also been used. Traditionally phage display has been used for antibody production, proteomics,<sup>48</sup> therapeutics, diagnostics (specially for cancer applications), infectious diseases and drug discovery.<sup>49,50</sup> Phage display has also been used for epitope mapping, a method to identify the epitope of the antigen that interacts with an antibody. The identification of epitopes is important for the development of diagnostic tools, vaccines and new therapeutic targets.<sup>51,52</sup> Additionally, phage display

has proven useful in targeting membrane receptors *via* the identification of their agonists and antagonists, which present biological applications as drugs for various diseases.<sup>53</sup> Phage display is also an excellent tool for the identification of protein–protein interactions.<sup>54–57</sup> Its biggest advantage, compared to other methods established in the protein–protein interactions field, is that highly diverse peptide libraries can be constructed at low cost.<sup>56</sup> These are some of the applications of phage display. The list is even broader and even more applications are expected to arise as the methodology evolves.<sup>58–67</sup>

## 2. Applications of engineered phages

Herein, we discuss how genetically modified phages (listed in Table 1) are used in different fields (presented in Fig. 2).

### 2.1 Therapeutic applications

Natural phages have multiple barriers that could prevent them from being developed into viable phage therapeutic products. Issues can arise both from their entry to mammalian cells and from circumventing the immune response of the host. Modified phages can be developed to avoid inactivation by the host defense system and persist in the body, thus enhancing their therapeutic potential.

In this section, examples of recombinant phages as therapeutic agents for a variety of diseases are given. This includes phage therapy in mammalian hosts as well as phages as lethal delivery vehicles for prokaryotic hosts.

The T7 bacteriophage was genetically modified for a potential therapy of hepatitis B. Globally HCC (hepatocellular carcinoma) is the fifth most common cancer in men, and the eighth most common in women, and it was estimated that during the year 2000, more than 500 000 new cases arose.<sup>68</sup> The first step of hepatitis B virus (HBV) infection is the interaction between a cell surface receptor and the HBV envelope protein (specifically the PreS1 region). T7 phage was modified to display polypeptides of varying length (up to fifty amino acids) of the PreS1 region. This was achieved by fusing the peptides of interest (PreS1 region variants) to the C-terminus of the capsid protein gp10B from T7. It was suggested that this system could be enhanced by displaying amino acids of the first half of the PreS1

Table 1 Engineered bacteriophages and their applications

Engineered bacteriophage	Application
M13	Phage display, <sup>25–33</sup> lethal delivery agent, <sup>83</sup> engineered protein purification, <sup>84</sup> nanomaterials, <sup>87</sup> vaccinology <sup>109,110</sup>
M13KE	Pathogen detection <sup>100</sup>
T7	Phage display, <sup>39–43</sup> gene therapy, <sup>69</sup> biofilm control <sup>114</sup>
Lambda (λ)	Phage display, <sup>44–47</sup> vaccinology, <sup>46,70</sup> biocontrol <sup>116</sup>
T4	Phage display, <sup>37,38</sup> vaccinology <sup>72,112</sup>
φA1122	Pathogen detection <sup>106</sup>
A511	Pathogen detection <sup>104</sup>
HK620	Pathogen detection <sup>98</sup>
PBSPCA1	Agriculture <sup>108</sup>
fd	Phage display, <sup>34–36</sup> nanodevice fabrication and bottom-up manufacturing <sup>85,86</sup>




Fig. 2 A schematic representation of the synthetic bacteriophage applications discussed in this review.



region, which would increase modified phage uptake and hence the efficiency of desired gene transfer into the cell. This study introduces T7 display as a model system for gene delivery into mammalian host cells and elucidates recombinant phages expand upon natural phage therapy.<sup>69</sup>

Another example of therapeutic bacteriophage applications in mammalian systems is the display of a membrane glycoprotein, of H5 influenza virus, on bacteriophage lambda major capsid protein gpD.<sup>70</sup> Here the lambda bacteriophage is assembled without its major capsid protein first *in vivo*, and then a fusion of gpD and H5 influenza membrane glycoprotein is added *in vitro*. This approach can be used to 'decorate' gpD deficient phage with recombinant gpD fused proteins (which are heterologously expressed in insect cells). The recombinant phages bind to the receptors on red blood cells and create a lattice structure of interconnected virus and red blood cells. It is observed that two H5 influenza-specific monoclonal antibodies inhibit the binding of red blood cells to the recombinant phages. These modified phages mimic H5 influenza virus behavior by attaching to the red blood cells; this could potentially be exploited for the detection of influenza virus-specific antibodies in vaccine trials.<sup>71</sup>

T4 phage is another example of engineered phage use in vaccinology. The outer capsid protein of T4 phage was fused to a protective antigen from *Bacillus anthracis*, to develop a vaccine for anthrax. The fusion protein was expressed in *E. coli*, purified, and *in vitro* added to the assembled phage. The PA-T4 particles presented immunogenicity in mice in the absence of an adjuvant. This study provides a promising system for construction of customized vaccines against anthrax.<sup>72</sup>

Phages target bacteria more specifically than most antibiotics, and consequently have less effect on the human gut microbiome. However, lytic phages, whose concomitant cell lysis may result in the release of toxic substances (endotoxins) have encouraged the development of lysis-deficient phages. These lysis-deficient phages can be engineered by harnessing the phage machinery responsible for cell lysis. This consists of a membrane protein (normally deemed, holin) and endolysin or murein hydrolase. Holins form holes in the cell membrane, thus letting endolysin cross the membrane and degrade the peptidoglycan layer of the cell wall.<sup>73</sup> An example of engineering a recombinant phage that is lysis-deficient involves *Staphylococcus aureus* phage P954 where its endolysin gene was inactivated by a loss of function insertion.<sup>74</sup> Endolysin-deficient phages encoding lethal but non-lytic proteins are able to kill bacteria while reducing the endotoxin release.<sup>75</sup> Engineered non-lytic phages have been shown to be efficient in treating mice infected with *P. aeruginosa*, *E. coli* or *S. aureus* which present higher survival rates, due to the lower levels of endotoxin release.<sup>13,74,76,77</sup> Additionally, filamentous phages (which do not lyse the host) have been used for the specific delivery of lethal substances or genes to the site of infection.<sup>78</sup> Among possible genes, those encoding for modified holin,<sup>79</sup> lethal transcription regulator<sup>80</sup> and addiction toxins (which induce programmed cell death) have been reported.<sup>81,82</sup>

Modified phage particles can also be used as lethal delivery agents for efficient pathogen killing. A recent example is the

engineering of the filamentous phage M13 to carry an integrin binding peptide and a fragment of the polymorphic membrane protein D from the sexually transmitted pathogen *Chlamydia trachomatis* (Ct), as a possible way to eliminate Ct infection. Based on this report, the engineered phage was able to significantly reduce Ct infection in both primary endocervical and HeLa cells, addressing the current lack of treatments against *Chlamydia trachomatis*.<sup>83</sup>

## 2.2 Industrial applications

High-gradient magnetic fishing (HGMF) partially purifies target products from heterogeneous bioprocess liquors. In HGMF, the target product is captured using magnetic adsorbent particles in combination with high-gradient magnetic separation equipment. HGMF binding capacity of microbeads was increased by placing an engineered M13 bacteriophage monolayer on a superparamagnetic (SPM) core of microbeads. This was achieved by genetic and chemical modification of the M13 coat proteins, pIII (minor coat) and pVIII (major coat) respectively. pIII protein was modified at its N-terminus to enable its binding onto nitrilotriacetic acid or silica coated SPMs, respectively. pVIII protein subunits of wild-type M13 were chemically cross-linked to a carboxyl-functionalized bead permitting side-on linkage of the phage to the SPMs. The phage-SPM particles, when used to fish the desired antibodies, led to >90% purified product from high protein solutions in one purification step.<sup>84</sup>

fd filamentous phage has been engineered to increase the affinity of gold (Au) to its protein coat. This was achieved by substituting five amino acids on the N-terminal region of p8, the fd phage's major coat protein.<sup>85,86</sup> These studies show how recombinant phages can be coated with a metal of interest, demonstrating the potential of recombinant phages as self-assembling templates for applications in bottom up manufacturing.

In addition, M13 filamentous bacteriophage has been used as a scaffold for the self-assembly of cobalt manganese oxide nanowires to make LiO<sub>2</sub> battery electrodes. Here, the phage coat protein gpVIII is modified to display peptides of negatively charged amino acids, and is able to interact with cationic metal precursors (such as cobalt and manganese) resulting in high production yield oxides. These oxides formed LiO<sub>2</sub> battery electrodes which were more porous and had a higher specific heat capacity in comparison to carbon electrodes.<sup>87</sup>

## 2.3 Biodetection applications

One area in which synthetic phages are proving useful is biodetection, where one of their main advantages is that they can be quickly amplified in the targeted live bacteria, compared to PCR or antibody-wash detection systems (which subsequently incur more false positives from the detection of dead bacteria).<sup>88</sup> Early adoptions of biodetection with synthetic phages have focused on the insertion of reporter genes into naturally isolated phages.<sup>89-93</sup> Most of these methods comprise of either inserting luciferase genes into the phage genome, or of fusing fluorescent proteins to the phage capsid, mimicking the engineering strategy employed in phage display.<sup>94</sup> It should be emphasized that these



systems are far from just academic enquires. Sample6 recently launched its DETECT/L kit on the back of luciferase-based recombinant phage technologies.<sup>93</sup> The kit correctly identifies 50 *Listeria* species, as well as correctly excluding 30 non-listeria species that were subjected to testing. However, converting luciferase-based assays to more optimal multiplex assays (*i.e.* assays that detect more than one bacterial species in a given sample) may not be straightforward,<sup>95</sup> which is an issue that could be circumvented by fluorescent-based reporter systems with compatible emission and excitation wavelengths.<sup>96</sup>

The precision of phage host recognition has been explored for pathogen detection from environmental samples. Water quality control is one of the major concerns for public health as well as marine environment, and rapid methods need to be developed to allow accurate pathogen identification. One such method used a phage-based fluorescent biosensor 'phagosensor' prototype for enteric bacteria detection.<sup>97</sup> In this system, the synthesis of the fluorescent protein only occurs after it is delivered to *E. coli* TD2158 by temperate bacteriophage HK620 carrying the fluorescent gene.<sup>98</sup> The recombinant phages were incubated with the sample for one hour, followed by flow cytometry, which allowed sensitive detection of environmental *E. coli* TD2158 strain in diluted samples, and in mixed co-cultures. The established template was also successfully adapted to phage P22 to detect *Salmonella enterica Typhimurium*.<sup>99</sup>

Colorimetry is another method for detecting pathogenic bacteria in water. In this instance, the target bacterial strain, ER2378, is trapped on a syringe filter followed by infection of a specific phage, M13KE.<sup>100</sup> ER2378 is a lacZ $\alpha$ -complementing strain of *E. coli* that expresses the  $\omega$ -domain of the  $\beta$ -gal ( $\omega$ Gal) and the  $\alpha$ Gal peptide is cloned in an intergenic region of the M13KE genome.<sup>101,102</sup> Upon  $\alpha$ Gal peptide delivery to the bacterial strain,  $\alpha$ Gal is converted to the  $\beta$ -gal active form of  $\alpha$ Gal, which is detectable by colorimetric assay.<sup>100</sup>

Another example of bacteriophage-based pathogen detection is the high-intensity fluorophage that can detect *Mycobacterium tuberculosis*.<sup>103</sup> Phage A511 was modified to report cells of *Listeria* genus upon synthesis of a bacterial luciferase gene. The modified gene was placed downstream of the major capsid protein (cps) and was expressed upon phage infection of *Listeria* cells.<sup>104</sup>

*Yersinia pestis* is the etiological agent of the plague, which has seen a breakout of cases in America recently.<sup>105</sup> To detect *Yersinia pestis* in blood samples, a recombinant reporter phage containing bacterial luxAB reporter genes was inserted in an early-transcribed noncoding region of the plague-diagnostic lytic phage  $\phi$ A1122 by homologous recombination. Upon infection of *Yersinia pestis* with the recombinant  $\phi$ A1122, the bioluminescent phenotype was observed after 10 to 15 min.<sup>106</sup> In a following study, the reporter phage was assessed as a diagnostic tool for *Yersinia pestis* in samples taken directly from the blood. Even though it displayed 100% inclusivity for *Yersinia pestis*, some non-pestis *Yersinia* strains and *Enterobacteriaceae* also showed signal transduction. The reporter phage demonstrated rapid detection of antimicrobial susceptibility profiling upon antibiotic incubation of the blood samples. As a consequence these results suggest that the application of lytic reporter

phages to detect bacterial pathogens in blood samples could reduce the time to diagnosis for patients afflicted with.<sup>107</sup>

Phage-reporter systems were also developed for agricultural settings. *Pseudomonas cannabina* pv. *alisalensis* and *Pseudomonas syringae* pv. *maculicola* are both causative agents for diseases of *Brassicaceae* family. In a recent study, phage-based diagnostic was developed to identify the cause of bacterial blight. *P. cannabina* pv. *alisalensis* or PBSPCA1 phage was modified by integration of bacterial luxAB genes in the place of nonessential phoH gene using homologous recombination upon wild-type PBSPCA1 phage infection of *P. cannabina* pv. *alisalensis* BS91 containing luxAB expression cassette. A successful detection of *Pseudomonas cannabina* pv. *alisalensis* versus *Pseudomonas syringae* pv. *maculicola* resulted in more than 100-fold increase in bioluminescence within 4 hours of tissue harvesting.<sup>108</sup>

## 2.4 Veterinary applications

Genetically engineered phages have a wide range of applications in veterinary science and medicine. In the vast majority of cases, recombinant phages deliver antigens to be used for vaccination against animal diseases.

Recombinant M13 bacteriophage has been used to vaccinate pigs against the tapeworm *Taenia solium*, which causes cysticercosis, a disease to which humans and pigs are susceptible. KETc1, KETc12 and GK1 peptides were fused to coat protein gpVIII and a recombinant antigen KETc7 was displayed on coat protein gpIII. The pooled phages were successful in reducing the number of cysts in the murine model (990 in mice receiving M13 vs. 338 immunized with the pool of recombinant phage). Preliminary work demonstrated sporadic effectiveness for a small sample of pigs, but further studies were needed to corroborate this evidence.<sup>109</sup> Such a study was performed on a larger sample size, and significantly reduced the occurrence of cysticercosis in vaccinated pigs by 54.2%.<sup>110</sup>

Phages lambda and T4, as mentioned earlier in this review, have been used to vaccinate against human diseases. In this section, we briefly mention their application as possible vaccines against pathogens that target animals. Recombinant lambda phage can be used as a potential vaccine against porcine Circovirus 2,<sup>46</sup> a virus that causes post-weaning multisystemic wasting syndrome (PMWS), and has proved costly in the swine industry.<sup>111</sup>

In another study, the T4 bacteriophage was used to develop a vaccine against infectious bursal disease virus (vvIBDV), a virus that causes infectious bursal disease (IBD) in chickens. Immunization of chickens with the recombinant T4-VP2 phage resulted in no clinical death; however, some temporary bursal damages were observed.<sup>112</sup>

## 2.5 Biocontrol applications

Biocontrol is the regulation of pest/pathogen levels by biological means; a strategy that is being progressively favored by industry. One of the major problems in industrial processing is biofilm formation, and this is especially apparent in food industry.<sup>113</sup> To this end, T7 bacteriophage was modified to express dispersin B (DspB),<sup>114</sup> an enzyme produced by



*Actinobacillus actinomycetemcomitans*.<sup>115</sup> DspB acts via  $\beta$ -1,6-*N*-acetyl-*D*-glucosamine hydrolysis which disrupts biofilm formation and integrity. DspB was placed downstream of capsid gene 10B under the control of the strong T7 10 promoter. This allowed DspB to be expressed intracellularly so that its release would occur during cell lysis. The results showed that DspB expressing phage was significantly more effective at killing *E. coli* in comparison to wild-type T7 and wild-type T3 bacteriophages, and that this phage reduced the amount of biofilm by a factor of 2.6 in comparison to non-engineered T7 control phage.<sup>114</sup>

In another study lambda phage was engineered to deliver CRISPR/Cas system to sensitize bacteria with antibiotic resistance genes. Once delivered to a pathogen, the CRISPR/Cas system was transferable between bacterial hosts so that bacteria with antibiotic genes would be outcompeted. In addition, pathogens with acquired CRISPR/Cas were no longer susceptible to engineered lytic phage infection. This system showed effective reduction in infections of antibiotic-resistant pathogens and thus offering a potential biocontrol system for hospital surface treatment.<sup>116</sup>

### 3. Discussion

Natural phages may be a solution to a myriad of issues in agriculture, biocontrol, and medicine: in agriculture, they are applied against plant infections; in biocontrol, in the protection and control of crops and food products; and in medicine, a number of trials have explored their safety and efficacy.

Phage therapy has reached a critical juncture in its development. Natural phages are, according to current legislature, unpatentable, as they are no longer considered novel, having first been introduced over a century ago.<sup>117</sup> This prevents them from being commercially viable in industry, especially for big pharma corporations that have to undergo expensive clinical trials, and so is an impediment to the development of infrastructure that can deliver treatments to patients. The intellectual property of recombinant phages, on the other hand, can be secured, thus overcoming these issues. Yet recombinant phages do more than to provide opportunities for profit; they extend upon natural phages by creating additional functionalities (such as delivery of variety of cargos, *e.g.* depolymerase<sup>114</sup>) as well as overcoming some of their limitations.

One such limitation is that natural phages can induce a mammalian immune response upon their entry, a response that could be avoided by modifying the phage's coat protein. Nonetheless, in some instances, an overexcited immune response is desired, for example, when developing vaccines against viral particles. In the case of HBV, phage-displayed viral peptides can evoke immune response, and help identify the antibodies specific to these viral peptides.

Furthermore, by refactoring phage genomes,<sup>14</sup> phages could have their sequences rejigged to avoid host restriction systems, by removing the palindromic sequences targeted by type II restriction enzymes, or by appending peptides that inhibit the CRISPR/Cas proteins. One can also envisage the swapping or addition of exogenous endo/exonucleases to cleave host genomes faster.

Further work demonstrated that rational engineering of tail fibres can change host tropism of bacteriophages<sup>1–6</sup> and pyocins<sup>118,119</sup> (phage-like particles called bacteriocins, produced by some strains of *Pseudomonas aeruginosa* for use in intra-species warfare). Employing this in combination with directed evolution, phage cocktails could be generated to target a given pathogen through separate, or a combination of, receptors, and adapted to circumvent the host-immune system. Importantly, new techniques are constantly being developed in the fields of genome engineering and gene synthesis, decreasing also the cost of gene synthesis. It is expected that also because of that, the engineering of recombinant bacteriophages will be further facilitated and will enable the corresponding broadening of their applications.

In summary, although there are still ethical, socio-economical, and experimental issues to resolve, the groundwork of phages appears promising, and will surely come to establish itself at the forefront of personalized therapeutics and diagnostics.

### Conflicts of interest

The authors declare no competing financial interests.

### Acknowledgements

The work is supported by the grants FP7-ICT-FET 610730 (EVOPROG), EPSRC-BBSRC BB/M017982/1 (WISB centre) and the startup allocation grant from the School of Life Sciences to A. J. A. P. S. is funded by FP7-ICT-FET 610730 (EVOPROG). A. G. is funded by a doctoral fellowship from the EPSRC & BBSRC Centre for Doctoral Training in Synthetic Biology (grant EP/L016494/1). P. M. is funded by a doctoral fellowship from the EPSRC Doctoral Training Centre *Molecular Organisation and Assembly in Cells* (Grant No. EP/F500378/1). We also wish to acknowledge Matthew Tridgett for contributing to Fig. 1.

### References

- 1 R. Marzari, D. Sblattero, M. Righi and A. Bradbury, *Gene*, 1997, **185**, 27–33.
- 2 F. Pouillot, H. Blois and F. Iris, *Biosecur Bioterror*, 2010, **8**, 155–169.
- 3 H. Ando, S. Lemire, D. P. Pires and T. K. Lu, *Cell Syst.*, 2015, **1**, 187–196.
- 4 J. R. Meyer, D. T. Dobias, J. S. Weitz, J. E. Barrick, R. T. Quick and R. E. Lenski, *Science*, 2012, **335**, 428–432.
- 5 F. Mahichi, A. J. Synnott, K. Yamamichi, T. Osada and Y. Tanji, *FEMS Microbiol. Lett.*, 2009, **295**, 211–217.
- 6 M. Yoichi, M. Abe, K. Miyanaga, H. Unno and Y. Tanji, *J. Biotechnol.*, 2005, **115**, 101–107.
- 7 E. W. Kovacs, J. M. Hooker, D. W. Romanini, P. G. Holder, K. E. Berry and M. B. Francis, *Bioconjugate Chem.*, 2007, **18**, 1140–1147.
- 8 I. Yacoby, H. Bar and I. Benhar, *Antimicrob. Agents Chemother.*, 2007, **51**, 2156–2163.



9 M. L. Embleton, S. P. Nair, W. Heywood, D. C. Menon, B. D. Cookson and M. Wilson, *Antimicrob. Agents Chemother.*, 2005, **49**, 3690–3696.

10 T. K. Lu and J. J. Collins, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 4629–4634.

11 E. G. Gladstone, I. J. Molineux and J. J. Bull, *J. Biol. Eng.*, 2012, **6**, 13.

12 S. P. Denyer, N. A. Hodges and S. P. Gorman, *Hugo and Russell's pharmaceutical microbiology*, John Wiley & Sons, 8th edn, 2008.

13 V. D. Paul, S. Sundarraj, S. S. Rajagopalan, S. Hariharan, N. Kempashanaiah, S. Padmanabhan, B. Sriram and J. Ramachandran, *BMC Microbiol.*, 2011, **11**, 195.

14 L. Y. Chan, S. Kosuri and D. Endy, *Mol. Syst. Biol.*, 2005, **1**, 0018.

15 L. J. Marinelli, M. Piuri, Z. Swigonova, A. Balachandran, L. M. Oldfield, J. C. van Kessel and G. F. Hatfull, *PLoS One*, 2008, **3**, e3957.

16 T. Feher, I. Karcagi, F. R. Blattner and G. Posfai, *J. Microb. Biotechnol.*, 2012, **5**, 466–476.

17 U. Qimron, B. Marincheva, S. Tabor and C. C. Richardson, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 19039–19044.

18 M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna and E. Charpentier, *Science*, 2012, **337**, 816–821.

19 R. Kiro, D. Shitrit and U. Qimron, *RNA Biol.*, 2014, **11**, 42–44.

20 B. Martel and S. Moineau, *Nucleic Acids Res.*, 2014, **42**, 9504–9513.

21 Y. Husimi, *Adv. Biophys.*, 1989, **25**, 1–43.

22 C. R. Merril, B. Biswas, R. Carlton, N. C. Jensen, G. J. Creed, S. Zullo and S. Adhya, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 3188–3192.

23 K. M. Esveld, J. C. Carlson and D. R. Liu, *Nature*, 2011, **472**, 499–503.

24 J. C. Carlson, A. H. Badran, D. A. Guggiana-Nilo and D. R. Liu, *Nat. Chem. Biol.*, 2014, **10**, 216–222.

25 W. Markland, B. L. Roberts, M. J. Saxena, S. K. Guterman and R. C. Ladner, *Gene*, 1991, **109**, 13–19.

26 D. Bhardwaj, S. S. Singh, S. Abrol and V. K. Chaudhary, *J. Immunol. Methods*, 1995, **179**, 165–175.

27 B. L. Roberts, W. Markland and R. C. Ladner, *Methods Enzymol.*, 1996, **267**, 68–82.

28 J. A. Chappel, M. He and A. S. Kang, *J. Immunol. Methods*, 1998, **221**, 25–34.

29 T. Belien, K. Hertveldt, K. Van den Brande, J. Robben, S. Van Campenhout and G. Volckaert, *J. Biotechnol.*, 2005, **115**, 249–260.

30 S. S. Sidhu, B. K. Feld and G. A. Weiss, *Methods Mol. Biol.*, 2007, **352**, 205–219.

31 K. Hertveldt, T. Belien and G. Volckaert, *Methods Mol. Biol.*, 2009, **502**, 321–339.

32 D. Ghosh, Y. Lee, S. Thomas, A. G. Kohli, D. S. Yun, A. M. Belcher and K. A. Kelly, *Nat. Nanotechnol.*, 2012, **7**, 677–682.

33 Y. Ivarsson, R. Arnold, M. McLaughlin, S. Nim, R. Joshi, D. Ray, B. Liu, J. Teyra, T. Pawson, J. Moffat, S. S. Li, S. S. Sidhu and P. M. Kim, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, 2542–2547.

34 M. Tornetta, S. Baker, B. Whitaker, J. Lu, Q. Chen, E. Pisors, L. Shi, J. Luo, R. Sweet and P. Tsui, *J. Immunol. Methods*, 2010, **360**, 39–46.

35 J. W. Gillespie, A. L. Gross, A. T. Puzyrev, D. Bedi and V. A. Petrenko, *Front Microbiol.*, 2015, **6**, 628.

36 A. Prisco and P. De Berardinis, *Int. J. Mol. Sci.*, 2012, **13**, 5179–5194.

37 V. P. Efimov, I. V. Nepluev and V. V. Mesyanzhinov, *Virus Genes*, 1995, **10**, 173–177.

38 M. Gamkrelidze and K. Dabrowska, *Arch. Microbiol.*, 2014, **196**, 473–479.

39 H. M. Li, K. Guo, Z. Yu, R. Feng and P. Xu, *Thorac. Cancer*, 2015, **6**, 469–474.

40 C. L. Wong, C. C. Sieo and W. S. Tan, *J. Virol. Methods*, 2013, **193**, 611–619.

41 M. Tsuboyama and I. Maeda, *J. Biosci. Bioeng.*, 2013, **116**, 28–33.

42 S. Liu, Y. Sun, H. Chen, S. Song and Y. Xu, *Appl. Biochem. Biotechnol.*, 2010, **162**, 1206–1213.

43 M. Dai, J. Temirov, E. Pesavento, C. Kiss, N. Velappan, P. Pavlik, J. H. Werner and A. R. Bradbury, *Protein Eng., Des. Sel.*, 2008, **21**, 413–424.

44 N. Sternberg and R. H. Hoess, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 1609–1613.

45 E. Pavoni, P. Vaccaro, V. D'Alessio, R. De Santis and O. Minenkov, *BMC Biotechnol.*, 2013, **13**, 79.

46 L. N. Gamage, J. Ellis and S. Hayes, *Vaccine*, 2009, **27**, 6595–6604.

47 R. Levy, I. J. Molineux, B. L. Iverson and G. Georgiou, *J. Immunol. Methods*, 2007, **321**, 164–173.

48 G. N. Sundell and Y. Ivarsson, *BioMed Res. Int.*, 2014, **2014**, 176172.

49 N. Lonberg, *Curr. Opin. Immunol.*, 2008, **20**, 450–459.

50 D. J. Christensen, E. B. Gottlin, R. E. Benson and P. T. Hamilton, *Drug Discovery Today*, 2001, **6**, 721–727.

51 L. F. Wang and M. Yu, *Curr. Drug Targets*, 2004, **5**, 1–15.

52 J. M. Gershoni, A. Roitburd-Berman, D. D. Siman-Tov, N. Tarnovitski Freund and Y. Weiss, *BioDrugs*, 2007, **21**, 145–156.

53 P. Molek, B. Strukelj and T. Bratkovic, *Molecules*, 2011, **16**, 857–887.

54 M. E. Kokoszka and B. K. Kay, *Methods Mol. Biol.*, 2015, **1248**, 173–188.

55 B. Addepalli, S. Rao and A. G. Hunt, *Methods Mol. Biol.*, 2015, **1255**, 147–158.

56 C. Blikstad and Y. Ivarsson, *Cell Commun. Signaling*, 2015, **13**, 38.

57 H. J. Ren, R. D. Liu, Z. Q. Wang and J. Cui, *Parasitol. Res.*, 2013, **112**, 1857–1863.

58 E. A. Coelho, M. A. Chavez-Fumagalli, L. E. Costa, C. A. Tavares, M. Soto and L. R. Goulart, *Rev. Soc. Bras. Med. Trop.*, 2015, **48**, 370–379.

59 K. A. Henry, M. Arbabi-Ghahroudi and J. K. Scott, *Front Microbiol.*, 2015, **6**, 755.

60 M. Hyvonen and P. Laakkonen, *Methods Mol. Biol.*, 2015, **1324**, 205–222.

61 H. Shim, *BMB Rep.*, 2015, **48**, 489–494.

62 K. Omidfar and M. Daneshpour, *Expert Opin. Drug Discovery*, 2015, **10**, 651–669.

63 D. Sanchez-Martin, M. D. Sorensen, S. Lykkemark, L. Sanz, P. Kristensen, E. Ruoslahti and L. Alvarez-Vallina, *Trends Biotechnol.*, 2015, **33**, 292–301.

64 G. A. Loset, G. Berntzen, T. Frigstad, S. Pollmann, K. S. Gunnarsen and I. Sandlie, *Front Oncol.*, 2014, **4**, 378.

65 E. C. Roncolato, L. B. Campos, G. Pessenda, L. Costa e Silva, G. P. Furtado and J. E. Barbosa, *Toxicon*, 2015, **93**, 79–84.

66 A. Zhao, M. R. Tohidkia, D. L. Siegel, G. Coukos and Y. Omidi, *Crit. Rev. Biotechnol.*, 2015, 1–14, DOI: 10.3109/07388551.2014.958978.

67 C. E. Chan, A. P. Lim, P. A. MacAry and B. J. Hanson, *Int. Immunol.*, 2014, **26**, 649–657.

68 F. X. Bosch, J. Ribes, M. Diaz and R. Cleries, *Gastroenterology*, 2004, **127**, S5–S16.

69 K. H. Tang, K. Yusoff and W. S. Tan, *J. Virol. Methods*, 2009, **159**, 194–199.

70 J. Mattiacio, S. Walter, M. Brewer, W. Domm, A. E. Friedman and S. Dewhurst, *Vaccine*, 2011, **29**, 2637–2647.

71 W. Domm, M. Brewer, S. F. Baker, C. Feng, L. Martinez-Sobrido, J. Treanor and S. Dewhurst, *J. Virol. Methods*, 2014, **197**, 47–50.

72 S. B. Shivachandra, M. Rao, L. Janosi, T. Sathaliyawala, G. R. Matyas, C. R. Alving, S. H. Leppla and V. B. Rao, *Virology*, 2006, **345**, 190–198.

73 I. Young, I. Wang and W. D. Roof, *Trends Microbiol.*, 2000, **8**, 120–128.

74 T. Matsuda, T. A. Freeman, D. W. Hilbert, M. Duff, M. Fuortes, P. P. Stapleton and J. M. Daly, *Surgery*, 2005, **137**, 639–646.

75 R. Young and U. Blasi, *FEMS Microbiol. Rev.*, 1995, **17**, 191–205.

76 S. Hagens, A. Habel, U. von Ahsen, A. von Gabain and U. Blasi, *Antimicrob. Agents Chemother.*, 2004, **48**, 3817–3822.

77 M. J. Catalao, F. Gil, J. Moniz-Pereira, C. Sao-Jose and M. Pimentel, *FEMS Microbiol. Rev.*, 2013, **37**, 554–571.

78 M. Russel, N. A. Linderoth and A. Sali, *Gene*, 1997, **192**, 23–32.

79 S. Hagens and U. Blasi, *Lett. Appl. Microbiol.*, 2003, **37**, 318–323.

80 Z. Moradpour, Z. Sepehrizadeh, F. Rahbarizadeh, A. Ghasemian, M. T. Yazdi and A. R. Shahverdi, *FEMS Microbiol. Lett.*, 2009, **296**, 67–71.

81 C. Westwater, L. M. Kasman, D. A. Schofield, P. A. Werner, J. W. Dolan, M. G. Schmidt and J. S. Norris, *Antimicrob. Agents Chemother.*, 2003, **47**, 1301–1307.

82 T. M. Viertel, K. Ritter and H. P. Horz, *J. Antimicrob. Chemother.*, 2014, **69**, 2326–2336.

83 S. R. Bhattacharai, S. Y. Yoo, S. W. Lee and D. Dean, *Biomaterials*, 2012, **33**, 5166–5174.

84 J. Muzard, M. Platt and G. U. Lee, *Small*, 2012, **8**, 2403–2411.

85 N. Korkmaz Zirpel, T. Arslan and H. Lee, *J. Colloid Interface Sci.*, 2015, **454**, 80–88.

86 N. Korkmaz, *Colloids Surf., B*, 2013, **112**, 219–228.

87 D. Oh, J. Qi, B. Han, G. Zhang, T. J. Carney, J. Ohmura, Y. Zhang, Y. Shao-Horn and A. M. Belcher, *Nano Lett.*, 2014, **14**, 4837–4845.

88 N. K. Petty, T. J. Evans, P. C. Fineran and G. P. Salmon, *Trends Biotechnol.*, 2007, **25**, 7–15.

89 S. Kim, M. Kim and S. Ryu, *Anal. Chem.*, 2014, **86**, 5858–5864.

90 M. Oda, M. Morita, H. Unno and Y. Tanji, *Appl. Environ. Microbiol.*, 2004, **70**, 527–534.

91 C. P. Kodikara, H. H. Crew and G. S. Stewart, *FEMS Microbiol. Lett.*, 1991, **67**, 261–265.

92 T. Funatsu, T. Taniyama, T. Tajima, H. Tadakuma and H. Namiki, *Microbiol. Immunol.*, 2002, **46**, 365–369.

93 M. Cappillino, R. P. Shivers, D. R. Brownell, B. Jacobson, J. King, P. Kocjan, M. Koeris, E. Tekeian, A. Tempesta, J. Bowers, E. Crowley, P. Bird, J. Benzinger and K. Fisher, *J. AOAC Int.*, 2015, **98**, 436–444.

94 G. P. Smith, *Science*, 1985, **228**, 1315–1317.

95 S. D. Alcaine, L. Tilton, M. A. Serrano, M. Wang, R. W. Vachet and S. R. Nugen, *Appl. Microbiol. Biotechnol.*, 2015, **99**, 8177–8185.

96 A. E. Smartt, T. Xu, P. Jegier, J. J. Carswell, S. A. Blount, G. S. Sayler and S. Ripp, *Anal. Bioanal. Chem.*, 2012, **402**, 3127–3146.

97 M. Vinay, N. Franche, G. Gregori, J. R. Fantino, F. Pouillot and M. Ansaldi, *PLoS One*, 2015, **10**, e0131466.

98 B. P. Cormack, R. H. Valdivia and S. Falkow, *Gene*, 1996, **173**, 33–38.

99 K. A. Datsenko and B. L. Wanner, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 6640–6645.

100 R. Derda, M. R. Lockett, S. K. Tang, R. C. Fuller, E. J. Maxwell, B. Breiten, C. A. Cudde, A. Ozdogan and G. M. Whitesides, *Anal. Chem.*, 2013, **85**, 7213–7220.

101 K. A. Noren and C. J. Noren, *Methods*, 2001, **23**, 169–178.

102 J. Norrander, T. Kempe and J. Messing, *Gene*, 1983, **26**, 101–106.

103 P. Jain, T. E. Hartman, N. Eisenberg, M. R. O'Donnell, J. Kriakov, K. Govender, M. Makume, D. S. Thaler, G. F. Hatfull, A. W. Sturm, M. H. Larsen, P. Moodley and W. R. Jacobs, Jr., *J. Clin. Microbiol.*, 2012, **50**, 1362–1369.

104 M. J. Loessner, M. Rudolf and S. Scherer, *Appl. Environ. Microbiol.*, 1997, **63**, 2961–2965.

105 H. A. Hill, L. D. Elam-Evans, D. Yankey, J. A. Singleton and M. Kolasa, *MMWR Morb Mortal Wkly Rep.*, 2015, **64**, 889–896.

106 D. A. Schofield, I. J. Molineux and C. Westwater, *J. Clin. Microbiol.*, 2009, **47**, 3887–3894.

107 J. P. Vandamm, C. Rajanna, N. J. Sharp, I. J. Molineux and D. A. Schofield, *J. Clin. Microbiol.*, 2014, **52**, 2998–3003.

108 D. A. Schofield, C. T. Bull, I. Rubio, W. P. Wechter, C. Westwater and I. J. Molineux, *Appl. Environ. Microbiol.*, 2012, **78**, 3592–3598.

109 K. Manoutcharian, A. Diaz-Orea, G. Gevorkian, G. Fragoso, G. Acero, E. Gonzalez, A. De Aluja, N. Villalobos, E. Gomez-Conde and E. Sciutto, *Vet. Immunol. Immunopathol.*, 2004, **99**, 11–24.



110 J. Morales, J. J. Martinez, K. Manoutcharian, M. Hernandez, A. Fleury, G. Gevorkian, G. Acero, A. Blancas, A. Toledo, J. Cervantes, V. Maza, F. Quet, H. Bonnabau, A. S. de Aluja, G. Fragoso, C. Larralde and E. Sciutto, *Vaccine*, 2008, **26**, 2899–2905.

111 J. C. Harding, C. D. Baker, A. Tumber, K. A. McIntosh, S. E. Parker, D. M. Middleton, J. E. Hill, J. A. Ellis and S. Krakowka, *J. Vet. Diagn. Invest.*, 2008, **20**, 274–282.

112 Y. C. Cao, Q. C. Shi, J. Y. Ma, Q. M. Xie and Y. Z. Bi, *Acta Biochim. Biophys. Sin.*, 2005, **37**, 657–664.

113 R. Van Houdt and C. W. Michiels, *J. Appl. Microbiol.*, 2010, **109**, 1117–1131.

114 T. K. Lu and J. J. Collins, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 11197–11202.

115 Y. Itoh, X. Wang, B. J. Hinnebusch, J. F. Preston and T. Romeo, 3rd, *J. Bacteriol.*, 2005, **187**, 382–387.

116 I. Yosef, M. Manor, R. Kiro and U. Qimron, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 7267–7272.

117 K. Thiel, *Nat. Biotechnol.*, 2004, **22**, 31–36.

118 S. R. Williams, D. Gebhart, D. W. Martin and D. Scholl, *Appl. Environ. Microbiol.*, 2008, **74**, 3868–3876.

119 D. Scholl, M. Cooley, S. R. Williams, D. Gebhart, D. Martin, A. Bates and R. Mandrell, *Antimicrob. Agents Chemother.*, 2009, **53**, 3074–3080.

